Study: Single daily ribavirin dose doesn't increase adverse effects

03/27/2013 | Medscape (free registration)

Researchers at the Icahn School of Medicine at Mount Sinai in New York found once-daily ribavirin treatment did not increase the risk of adverse gastrointestinal events in hepatitis C patients being treated with triple therapy. The results were presented at the International Conference on Viral Hepatitis.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID